☰

Yi Zeng, Ph.D. - Publications

Affiliations: 
2003 University of Arizona, Tucson, AZ 
Area:
Immunology, Oncology
Tree Info Similar researchers PubMed Report error

31 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Zhu Q, Yang Y, Zeng Y, Chen K, Zhang Q, Wang L, Huang Y, Jian S. The significance of CD8 tumor-infiltrating lymphocytes exhaustion heterogeneity and its underlying mechanism in diffuse large B-cell lymphoma. International Immunopharmacology. 137: 112447. PMID 38909497 DOI: 10.1016/j.intimp.2024.112447  0.307
2024 Zeng Y, Wei S, Sun J, Xu N. [Application of mRNA nano-delivery system in CAR-T tumor immunotherapy]. Sheng Wu Gong Cheng Xue Bao = Chinese Journal of Biotechnology. 40: 1338-1351. PMID 38783801 DOI: 10.13345/j.cjb.230541  0.349
2020 Molina MS, Stokes J, Hoffman EA, Eremija J, Zeng Y, Simpson RJ, Katsanis E. Bendamustine Conditioning Skews Murine Host DCs Toward Pre-cDC1s and Reduces GvHD Independently of Batf3. Frontiers in Immunology. 11: 1410. PMID 32765499 DOI: 10.3389/Fimmu.2020.01410  0.575
2020 Stokes J, Hoffman EA, Molina MS, Kummet N, Simpson RJ, Zeng Y, Katsanis E. Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia. Oncoimmunology. 9: 1758011. PMID 32391190 DOI: 10.1080/2162402X.2020.1758011  0.599
2018 Stokes J, Hoffman EA, Molina MS, Eremija J, Larmonier N, Zeng Y, Katsanis E. Bendamustine with total body irradiation limits murine graft-versus-host disease in part through effects on myeloid-derived suppressor cells. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30326280 DOI: 10.1016/J.Bbmt.2018.10.009  0.573
2018 Katsanis E, Sapp LN, Varner N, Koza S, Stea B, Zeng Y. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide/bendamustine in pediatric and young adult patients with hematologic malignancies. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29908231 DOI: 10.1016/J.Bbmt.2018.06.007  0.521
2018 Sun L, Hao Y, Wang Z, Zeng Y. Constructing TC-1-GLUC-LMP2 Model Tumor Cells to Evaluate the Anti-Tumor Effects of LMP2-Related Vaccines. Viruses. 10. PMID 29570629 DOI: 10.3390/v10040145  0.36
2017 Zeng Y, Hahn S, Stokes J, Hoffman EA, Schmelz M, Proytcheva M, Chernoff J, Katsanis E. Pak2 regulates myeloid-derived suppressor cell development in mice. Blood Advances. 1: 1923-1933. PMID 29296839 DOI: 10.1182/Bloodadvances.2017007435  0.644
2017 Zeng Y, Katsanis E. Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation. Bone Marrow Transplantation. PMID 28920946 DOI: 10.1038/Bmt.2017.186  0.541
2016 Katsanis E, Sapp LN, Pelayo-Katsanis L, Whitney K, Zeng Y, Kopp LM. Alternative Donor Hematopoietic Cell Transplantation Conditioned With Myeloablative Busulfan, Fludarabine, and Melphalan is Well Tolerated and Effective Against High-risk Myeloid Malignancies. Journal of Pediatric Hematology/Oncology. PMID 27467368 DOI: 10.1097/Mph.0000000000000621  0.522
2016 Stokes J, Hoffman EA, Zeng Y, Larmonier N, Katsanis E. Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation. British Journal of Haematology. PMID 27030315 DOI: 10.1111/Bjh.14034  0.551
2015 Zeng Y, Katsanis E. The complex pathophysiology of acquired aplastic anaemia. Clinical and Experimental Immunology. 180: 361-70. PMID 25683099 DOI: 10.1111/Cei.12605  0.627
2015 Zeng Y, Broxmeyer HE, Staser K, Chitteti BR, Park SJ, Hahn S, Cooper S, Sun Z, Jiang L, Yang X, Yuan J, Kosoff R, Sandusky G, Srour EF, Chernoff J, et al. Pak2 regulates hematopoietic progenitor cell proliferation, survival, and differentiation. Stem Cells (Dayton, Ohio). 33: 1630-41. PMID 25586960 DOI: 10.1002/Stem.1951  0.312
2015 Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger JC, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner G, et al. Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer. Journal of the National Cancer Institute. 107: 364. PMID 25424197 DOI: 10.1093/jnci/dju364  0.345
2014 Zeng Y, Stokes J, Hahn S, Hoffman E, Katsanis E. Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD. Bone Marrow Transplantation. 49: 1076-83. PMID 24777185 DOI: 10.1038/Bmt.2014.91  0.613
2008 Mo WN, Zhou L, Wang Z, Tang AZ, Huang GW, Zeng Y. [Dendritic cells transfected with recombinant adenovirus Ad5F35-LMP2 induces LMP2 specific immunity mediated by cytotoxic T lymphocytes in vitro]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi = Zhonghua Shiyan He Linchuang Bingduxue Zazhi = Chinese Journal of Experimental and Clinical Virology. 22: 254-6. PMID 19105335  0.312
2007 Li G, Zeng Y, Chen X, Larmonier N, Sepassi M, Graner MW, Andreansky S, Brewer MA, Katsanis E. Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. Clinical and Experimental Immunology. 148: 136-45. PMID 17349014 DOI: 10.1111/J.1365-2249.2007.03323.X  0.612
2007 Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, Thompson S, Chen X, Andreansky S, Katsanis E. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunology, Immunotherapy : Cii. 56: 48-59. PMID 16612596 DOI: 10.1007/S00262-006-0160-8  0.67
2006 Zeng Y, Chen X, Larmonier N, Larmonier C, Li G, Sepassi M, Marron M, Andreansky S, Katsanis E. Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination. International Journal of Cancer. Journal International Du Cancer. 119: 2624-31. PMID 16989012 DOI: 10.1002/Ijc.22150  0.673
2006 Pan Y, Zhang J, Zhou L, Zuo J, Zeng Y. In vitro anti-tumor immune response induced by dendritic cells transfected with EBV-LMP2 recombinant adenovirus. Biochemical and Biophysical Research Communications. 347: 551-7. PMID 16842756 DOI: 10.1016/j.bbrc.2006.05.214  0.315
2006 Chen X, Zeng Y, Li G, Larmonier N, Graner MW, Katsanis E. Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 12: 275-83. PMID 16503496 DOI: 10.1016/J.Bbmt.2006.01.001  0.673
2006 Zeng Y, Graner MW, Katsanis E. Chaperone-rich cell lysates, immune activation and tumor vaccination. Cancer Immunology, Immunotherapy : Cii. 55: 329-38. PMID 15887013 DOI: 10.1007/S00262-005-0694-1  0.671
2005 Zeng Y, Graner MW, Thompson S, Marron M, Katsanis E. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. Blood. 105: 2016-22. PMID 15374884 DOI: 10.1182/Blood-2004-05-1915  0.631
2004 Feng H, Zeng Y, Graner MW, Whitesell L, Katsanis E. Evidence for a Novel, Caspase-8-Independent, Fas Death Domain-Mediated Apoptotic Pathway. Journal of Biomedicine & Biotechnology. 2004: 41-51. PMID 15123887 DOI: 10.1155/S1110724304308041  0.633
2004 Zeng Y, Graner MW, Feng H, Li G, Katsanis E. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. International Journal of Cancer. Journal International Du Cancer. 110: 251-9. PMID 15069690 DOI: 10.1002/Ijc.20115  0.727
2003 Graner MW, Zeng Y, Feng H, Katsanis E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunology, Immunotherapy : Cii. 52: 226-34. PMID 12669247 DOI: 10.1007/S00262-002-0359-2  0.683
2003 Zeng Y, Feng H, Graner MW, Katsanis E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood. 101: 4485-91. PMID 12576309 DOI: 10.1182/Blood-2002-10-3108  0.733
2003 Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood. 101: 245-52. PMID 12393411 DOI: 10.1182/Blood-2002-05-1580  0.745
2002 Feng H, Zeng Y, Graner MW, Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood. 100: 4108-15. PMID 12393401 DOI: 10.1182/Blood-2002-05-1389  0.728
2001 Feng H, Zeng Y, Whitesell L, Katsanis E. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood. 97: 3505-12. PMID 11369644 DOI: 10.1182/Blood.V97.11.3505  0.732
2001 He L, Feng H, Raymond A, Kreeger M, Zeng Y, Graner M, Whitesell L, Katsanis E. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunology, Immunotherapy : Cii. 50: 31-40. PMID 11315508 DOI: 10.1007/Pl00006680  0.722
Show low-probability matches.